Why It's Time to Rethink How We Measure HCP Engagement

In the world of B2B pharmaceutical marketing, email remains a cornerstone for reaching healthcare professionals (HCPs). But recent years have brought a growing challenge: non-human engagement.
As enterprise-level email security solutions become more advanced, they increasingly interfere with our ability to measure true human interaction. Emails appear to be opened and links clicked—sometimes within seconds of being sent—yet the intended recipient may never have laid eyes on the message.
The result? Inflated metrics, confused attribution models, and misleading signals about campaign performance. It’s time to talk about how we fix this.


Many HCPs work within large hospital networks, health systems, or academic institutions that rely on robust security platforms like Proofpoint, Mimecast, Barracuda, and Microsoft Defender for Office 365. These tools are designed to protect inboxes from phishing, malware, and spam. But they do so by:
What this creates is a paradox for marketers: the more secure your audience’s environment, the more difficult it is to trust your performance metrics.

Here’s a quick breakdown of what these platforms do and how it affects marketers:
| Security Feature | Impact on Metrics |
| Image pre-fetching | Triggers false opens |
| Link scanning | Inflates click rates |
| Bot-based routing | Masks true user identity and behavior |
| Proxy IPs | Impairs geo and device-based segmentation |
False positives are especially common with links tied to “Request a Rep,” “Contact Us,” or form submissions—calls-to-action that security bots often flag due to anchor tags or specific URL patterns.


At Ascender, we’ve implemented a multi-layered strategy using Marketo, Google Analytics 4 (GA4), and manual analysis. Here’s how we’re reducing noise and regaining clarity:
1. Marketo Bot Activity Filters
2. OS-Based Suppression
3. Honeypot Links
4. Time-Based Flagging
5. GA4 Zero-Second Sessions


We’ve had to pivot away from vanity metrics like opens and clicks and focus on downstream, high-intent actions, such as:
These pull-through metrics provide a truer picture of HCP interest and help us differentiate between bots and real human behavior.


Other B2B marketers—especially in sectors like tech, finance, and enterprise SaaS—are dealing with similar challenges. Emerging strategies include:
One promising direction is the use of AI classifiers that analyze time, sequence, source, and behavior patterns to flag anomalies. We’re exploring this at Ascender as a future-proof way to improve report fidelity (pending internal feasibility conversations).

As we continue refining our approach, we’re actively asking:


Non-human engagement is here to stay, and so are the bots. As security systems become more aggressive, we must become more adaptive.
The future of email marketing—especially in regulated, high-barrier industries like pharma—is not about chasing opens or clicks. It’s about real interactions, real actions, and real results.
At Ascender, we’re reimagining how B2B pharma marketers can track success in a way that reflects human behavior—not just firewall noise.